Abstract A33: Biomarkers of Cdk5 driven neuroendocrine tumors
Conclusion: Four novel phosphoproteins downstream of Cdk5 comprise a set of biomarkers for Cdk5-dependent human NE tumors. The combination of these biomarkers with pathway specific therapies currently under development will constitute a coupled diagnostic-therapeutic regimen for personalized treatment of NE cancer patients.Citation Format: Angela M. Carter, Rahul Telange, Sarah Oltmann, Fiemu Nwariaku, Bruce Robinson, Elizabeth Grubbs, James Bibb. Biomarkers of Cdk5 driven neuroendocrine tumors. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr A33.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Carter, A. M., Telange, R., Oltmann, S., Nwariaku, F., Robinson, B., Grubbs, E., Bibb, J. Tags: Other Topics: Poster Presentations - Proffered Abstracts Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Genetics | Lung Cancer | Men | Multiple Endocrine Neoplasia | Multiple Endocrine Neoplasia Syndrome | Neurology | Pancreas | Pancreatic Cancer | Study | Thyroid | Thyroid Cancer